MBC

United Nations Global Compact announces its 2023 SDG Pioneers

Retrieved on: 
Wednesday, September 20, 2023
Strauss Group, Social impact, Sustainable Development Goals and Nigeria, Sustainable Development Goals, MFI, United Nations Global Compact, Ten Principles for the Establishment of a Monolithic Ideological System, Sustainability, MBC, UN, DBL Group, Sustainable development, Environment, Responsibility, Biodiversity, Tourism, Management, Drug, Ethics

New York, United States of America, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The United Nations Global Compact today announced twelve new SDG Pioneers — business leaders who are doing an exceptional job to advance the Sustainable Development Goals (SDGs) through the implementation of the Ten Principles of the UN Global Compact on human rights, environment, labour and anti-corruption.

Key Points: 
  • New York, United States of America, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The United Nations Global Compact today announced twelve new SDG Pioneers — business leaders who are doing an exceptional job to advance the Sustainable Development Goals (SDGs) through the implementation of the Ten Principles of the UN Global Compact on human rights, environment, labour and anti-corruption.
  • We hope their work will inspire others to advance the Global Goals by implementing our Ten Principles on human rights, labour, environment and anti-corruption,” said Sanda Ojiambo, CEO & Executive Director of the UN Global Compact.
  • The 2023 UN Global Compact SDG Pioneers are:
    Fanilo Rakotovao Rakotoarison, Social Impact Director, Axian Group, Madagascar.
  • The SDG Pioneer entries were judged by an expert panel of representatives of the UN Global Compact Board Members, alongside previous SDG Pioneers and representatives from academia and UN agencies.

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Wednesday, September 20, 2023
Oncology, Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, University, Civil service commission, Progression-free survival, Creatinine, Anemia, Triglyceride, ESR1, Neoplasm, Safety, CDK, Cholesterol, European Medicines Agency, MBC, Indigestion, Advanced Therapy Medicinal Product, Constipation, Woman, Mutation, Multimedia, SOC, Arthralgia, Doctor of Philosophy, Diarrhea, PFS, Abdominal pain, EMA, Committee for Medicinal Products for Human Use, Vomiting, Fatigue, European Institute, Back pain, European Institute of Oncology, IRCCS, HIV disease progression rates, MD, Patient, European, Risk, Division, Drug development, Nausea, Headache, CHMP, Death, Potassium, University of Milano-Bicocca, Disease, European Commission, ER, Breast cancer, Pharmaceutical industry

With this approval, ORSERDU is the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • With this approval, ORSERDU is the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • ESR1 mutations are acquired mutations that develop as a result of exposure to endocrine therapy, and they are found in up to 40% of patients with ER+, HER2- mBC.
  • ESR1 mutations are a known driver of resistance to standard endocrine therapy, and until now, the tumors that harbor these mutations have been more difficult to treat.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

MEDIA ALERT: WEBINAR: Ask Me Anything: Dr. David Clark on the Power of Measurement-based Care

Retrieved on: 
Tuesday, September 19, 2023
General Health, Mental Health, Other Health, Health, Practice Management, Knowledge, University, NHS, Partnership, Health informatics, MBC, Q&A, Psychology, Experimental psychology, Nursing, Session

To register for this webinar, please visit greenspacehealth.com/events .

Key Points: 
  • To register for this webinar, please visit greenspacehealth.com/events .
  • This virtual event is intended for a broad audience of behavioral health leaders and providers with varying levels of MBC knowledge.
  • Attendance at Session #1 is not required to register for this session.
  • Click below to explore key highlights from Session #1:

MasterBrand Announces Participation in Habitat for Humanity’s 37th Carter Work Project

Retrieved on: 
Tuesday, September 19, 2023
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Philanthropy, Interior Design, Other Philanthropy, Retail, Fund Raising, Foundation, Home Goods, Other Construction & Property, Heart, Partnership, Jimmy & Rosalynn Carter Work Project, Habitat for Humanity, Holiday, MBC, Platinum Partners, Bath, Humanity, NYSE, Hunting, Hotel, Habitat

“The kitchen is the heart of the home--and your cabinets are the backdrop for everything from family gatherings at holidays to daily meal prep and homework. We’ve designed these kitchens to combine long-lasting quality, durability, great looks, and the organizational features that help busy families,” said Leslie Haefling, MasterBrand’s lead designer for the Carter Work Project.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will be participating in Habitat for Humanity’s 2023 Jimmy and Rosalynn Carter Work Project and will serve as the project’s exclusive cabinet provider.
  • That is why our associates participate in Habitat for Humanity events from coast to coast—and some have done so for more than two decades.
  • We are extremely excited to be participating in the 2023 Carter Work Project and supporting Habitat in a more focused way,” said Dave Banyard, MasterBrand President and Chief Executive Officer.
  • The Carter Work Project is a marquee event for Habitat for Humanity, a global nonprofit housing organization, and MasterBrand’s partnership will directly support Charlotte families in a meaningful way.

MasterBrand Announces Participation in Zelman’s 2023 Virtual Housing Summit

Retrieved on: 
Thursday, September 14, 2023
Home Goods, Interior Design, Retail, Residential Building & Real Estate, Construction & Property, MBC, NYSE, Cryptocurrency, Management

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced that Dave Banyard, President and Chief Executive Officer, and Andi Simon, Executive Vice President and Chief Financial Officer, will participate in Zelman’s 2023 Virtual Housing Summit on September 21, 2023.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced that Dave Banyard, President and Chief Executive Officer, and Andi Simon, Executive Vice President and Chief Financial Officer, will participate in Zelman’s 2023 Virtual Housing Summit on September 21, 2023.
  • The Company will host virtual investor meetings throughout the day.

MasterBrand Named as One of America’s Safest Companies by EHS Today

Retrieved on: 
Wednesday, September 13, 2023
Construction & Property, Natural Resources, Other Manufacturing, Other Natural Resources, Other Construction & Property, Interior Design, Manufacturing, Forest Products, Injury, Agriculture, Security, Organization, EHS Today, MBC, ESG, NYSE, Conference, EHS, Video game, Nursing, Safety, Health

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, has been named one of America’s Safest Companies by EHS Today, the leading publication for safety professionals in the United States.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, has been named one of America’s Safest Companies by EHS Today, the leading publication for safety professionals in the United States.
  • “We are thrilled to be recognized as one of America’s Safest Companies by EHS Today.
  • EHS Today is the go-to publication on trends, management strategies, and regulatory updates helping organizations provide safe and healthy work sites.
  • MasterBrand will be presented with an award recognizing this achievement during a ceremony at EHS Today’s Safety Leadership Conference in Orlando, FL, September 18-20, 2023.

Andalusia Whiskey Co. Release Raises Money for Maui Wildfire Victims!

Retrieved on: 
Tuesday, September 12, 2023
Vanilla, Ageing, Tootsie Roll, MBC, Beer

BLANCO, Texas, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Andalusia Whiskey Co. long awaited collaboration with Maui Brewing Co. is donating $50 of every bottle sold to the Maui Wildfire Relief efforts.

Key Points: 
  • BLANCO, Texas, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Andalusia Whiskey Co. long awaited collaboration with Maui Brewing Co. is donating $50 of every bottle sold to the Maui Wildfire Relief efforts .
  • After the devastating fires, in Lahaina the time was right to release the whiskey and have it benefit victims of the wildfire."
  • After the devastating fires, in Lahaina (home of the original Maui Brewing Co. location) the time was right to release the whiskey and have it benefit victims of the wildfire."
  • Said Ty Phelps, Co-Found of Andalusia Whiskey Co.
    Sip us some delicious whiskey while helping us raise money ($50 for every bottle sold) for the Maui Wildfire Relief efforts.

Two Chairs Launches Group Therapy to Increase Mental Health Care Access

Retrieved on: 
Tuesday, August 29, 2023
ACT, Acceptance, Commitment, Clinical Care Classification System, Cognitive behavioral therapy, DBT, Kaiser Permanente, CBT, Patient, MBC, Mindfulness, Mental, SAN, Dialectical behavior therapy, Chair, Nursing, Pharmaceutical industry

As demand for mental health services continues to soar, high-quality therapy visionary expands mental health care to group format, extending the value of the therapist hour

Key Points: 
  • As demand for mental health services continues to soar, high-quality therapy visionary expands mental health care to group format, extending the value of the therapist hour
    New group therapy offering is rooted in rigorous therapist-patient matching principles, with patient and therapist collaborating on care modality and group selection
    Therapy groups embrace same bi-directional measurement processes as Two Chairs' individual therapy, driving higher treatment response rates, higher patient retention and helping patients reach remission faster
    SAN FRANCISCO, Aug. 29, 2023 /PRNewswire/ -- Two Chairs , a modern behavioral health company, today announced the launch of its group therapy offering, which increases access to mental health care services to more people and maximizes the value of the therapist hour.
  • Although not as prevalent as individual therapy, group therapy has long been shown to be as effective as individual therapy for a wide range of symptoms and conditions.
  • With the U.S. in a prolonged shortage of mental health care professionals, group therapy can also be more efficient.
  • Group therapy is also a major care access lever as the U.S. grapples with a mental health care provider shortage.

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women

Retrieved on: 
Tuesday, August 29, 2023
CMS, The Orange Book, NDA, Fulvestrant, Woman, Medicine, Research, Oncology, Orange Book, Patent, Patient, MBC, Physician, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tariff, Food, Breast cancer, Pharmaceutical industry, IQVIA, Eagle

WOODCLIFF LAKE, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women. EA-114 has the potential to provide healthcare providers with a formulation that meaningfully optimizes the dosing regimen for all fulvestrant patients. Eagle currently anticipates filing a new drug application (“NDA”) for EA-114 in 2024. If approved for all uses, EA-114 would allow physicians to provide a personalized treatment regimen to all patients, including specific sub-populations.

Key Points: 
  • Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women.
  • If approved for all uses, EA-114 would allow physicians to provide a personalized treatment regimen to all patients, including specific sub-populations.
  • Currently, fulvestrant is indicated as monotherapy first-line endocrine treatment in post-menopausal women with hormone receptor-positive metastatic breast cancer (MBC) and in combination therapy to treat hormone receptor positive, advanced breast cancer in women whose breast cancer has spread or worsened after being treated with anti-estrogen medications.
  • Eagle intends to provide additional updates on the progress of the EA-114 development program for the sub-populations as discussions with the FDA progress.

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
PDAC, Completeness, Rochester, Trastuzumab, Pathology, Merck Group, Cash, Astrocyte, Patient, FCMI, Observation, H. Lee Moffitt Cancer Center & Research Institute, Private placement, Three Months, Eurosport 1, University, Brain, Research, Lecanemab, TME, Motivation, Drug discovery, Neoplasm, FDA, B cell, Safety, Cognition, Neuron, ICI, G protein-coupled receptor, Metastatic breast cancer, DC1, Cancer, Lung cancer, CCR8, Immunotherapy, Antibody, PFS, ARIA, Publication, MBC, Biomarker, Microglia, SEMA4D, Security, ORR, HD, Head and neck cancer, Drug development, Nature, SIGNAL, Avelumab, Neurodegenerative disease, Pfizer, CO, Breast cancer, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, HNSCC, Merck

ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs. .

Key Points: 
  • Expect to Complete 12-months treatment in June, 2024
    ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.
  • Over the last few months, Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • In the first segment, completed on May 12, 2023, Vaccinex sold approximately 7.9 million shares of common stock for aggregate proceeds of $2.96 million.
  • For further details on Vaccinex’s financials, refer to its Form 10Q filed August 14, 2023 with the S.E.C.